Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials

Figures & data

Table 1. Estimated absolute risks for clinical events among NVAF patients treated with warfarin and individual oral anticoagulants (OACs).

Trial	ARISTOTLE				RE-LY				ROCKET-AF
Drug	Warfarin (%/patient-yr)		Apixaban (%/patient-yr)		Warfarin (%/patient-yr)		Dabigatran (%/patient-yr)		Warfarin (%/patient-yr)		Rivaroxaban(%/patient-yr)
Age group	≥75	<75	≥75	<75	≥75	<75	≥75	<75	≥75	<75	≥75	<75
SSE	2.20	1.35	1.60	1.17	2.14	1.43	1.43	0.90	2.78	0.11	2.24	1.99
MI*	0.61	0.61	0.53	0.53	0.53	0.53	0.74	0.74	1.12	1.12	0.91	0.91
PE/DVT*	0.05	0.05	0.04	0.04	0.09	0.09	0.15	0.15	NR	NR	NR	NR
MBEHS	4.56	1.84	3.00	1.43	3.89	2.72	4.97	2.04	3.35	2.65	4.13	2.76
Non-major bleedings**	22.71	22.71	14.41	16.79	16.37	16.37	19.10	11.42	13.43	13.43	15.34	13.36

SSE, stroke and systemic embolism; MI, myocardial infarction; PE/DVT, pulmonary embolism or deep-vein thrombosis; MBEHS, major bleedings excluding hemorrhagic stroke; NR, not reported.

*The event rates of the secondary end-points, MI and PE/DVT were assumed not to vary with age since such data were not reported in the NOAC clinical trials and those from the overall trial population were used.

**These bleeding rates were not reported by age group and the relative risks of these bleedings were assumed to be the same as those of major bleedings for the corresponding age group population.

Figure 1. Differences in One Year Medical Costs for Clinical Events Among NVAF Patients Treated with Individual Oral Anticoagulants (OACs) Relative to Warfarin-treated Patients.

Table 2. Medical costs for clinical events among NVAF patients treated with warfarin and individual oral anticoagulants (OACs).

Trial	ARISTOTLE				RE-LY				ROCKET-AF
Drug	Warfarin ($/patient-yr)		Apixaban ($/patient-yr)		Warfarin ($/patient-yr)		Dabigatran ($/patient-yr)		Warfarin ($/patient-yr)		Rivaroxaban ($/patient-yr)
Age group	≥75	<75	≥75	<75	≥75	<75	≥75	<75	≥75	<75	≥75	<75
SSE	893	548	650	475	869	581	581	366	1128	856	911	808
MI*	228	228	198	198	198	198	277	277	419	419	341	341
PE/DVT*	10	10	8	8	18	18	29	29	NR	NR	NR	NR
MBEHS	1579	637	1040	497	1347	942	1721	706	1159	918	1430	957
Non-major bleedings**	30	30	19	22	21	21	25	15	18	18	20	17
Total cost	2740	1453	1915	1200	2454	1760	2633	1393	2725	2212	2701	2123

SSE, stroke and systemic embolism; MI, myocardial infarction; PE/DVT, pulmonary embolism or deep-vein thrombosis; MBEHS, major bleedings excluding hemorrhagic stroke; NR, not reported.